

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)



(10) International Publication Number
WO 2021/203200 A1

(51) International Patent Classification:

C12N 5/10 (2006.01) *C07K 19/00* (2006.01)
A61K 31/7088 (2006.01) *C12N 15/113* (2010.01)
A61K 31/7105 (2006.01) *C12N 15/54* (2006.01)
A61K 35/17 (2015.01) *C12N 15/62* (2006.01)
A61K 38/46 (2006.01) *C12N 15/63* (2006.01)
A61P 35/00 (2006.01) *C12N 5/0783* (2010.01)
A61P 37/02 (2006.01) *C12N 9/22* (2006.01)

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/CA2021/050464

(22) International Filing Date:

07 April 2021 (07.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/006,455 07 April 2020 (07.04.2020) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK**
[CA/CA]; 190 Elizabeth Street, R. Fraser Elliott Building -
Room 1S-417, Toronto, Ontario M5G 2C4 (CA).

(72) Inventors: **DINIZ DE CARVALHO, Daniel**; 31 Drummondville Lane, Toronto, Ontario M4E 3X7 (CA). **HE, Housheng**; 18 Bathford Crescent, TORONTO, Ontario M2J 2S4 (CA). **ETTAYEBI, Ilias**; 22-2155 Duncaster Drive, Burlington, Ontario L7P 4R4 (CA). **SOARES, Fraser**; 105-25 Esterbrooke Avenue, Toronto, Ontario M2J 2C5 (CA). **LOO YAU, Helen**; 2004-386 Yonge Street, Toronto, Ontario M5B 0A5 (CA).

(74) Agent: **NORTON ROSE FULBRIGHT CANADA LLP**;
1 Place Ville Marie, Suite 2500, Montreal, Québec H3B 1R1 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

(54) Title: COMPOSITIONS AND METHODS FOR ENHANCING ACTIVATION AND CYTOLYTIC ACTIVITY OF CD8⁺ T CELLS THROUGH DISRUPTION OF THE SAGA (SPT-ADA-GCN5-ACETYLTRANSFERASE) COMPLEX

(57) Abstract: Methods of increasing T cell effector function in a T cell population are provided that involve inhibiting one or more genetic subunits of the SAGA (Spt-Ada-Gcn5-acetyltransferase) gene regulation complex in the T cell population. Also provided are methods of using such T cell populations in the treatment of cancer patients.



WO 2021/203200 A1